Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk

Dow Jones

2024-12-19

1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a "buy the rumor, sell the news," reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com)

(END) Dow Jones Newswires

December 18, 2024 13:49 ET (18:49 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492378861"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492378861\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492378861?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 02:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492378861","market":"us","top_or_hot":-1,"title":"Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 13:49 ET (18:49 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-19 02:49</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 13:49 ET (18:49 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美國抗疫概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492378861","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492378861","pubTimestamp":1734547740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技","CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"尽管首席执行官发表乐观言论，Corvus Pharmaceuticals仍暴跌——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 13:49 ET (18:49 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}